See the DrugPatentWatch profile for humira
When does Humira’s patent expire (and what does that mean in practice)?
Humira (adalimumab) does not have a single, simple “patent expiry date.” Multiple patent rights and exclusivities span different parts of the product (for example, the original molecule and later changes). That means the market date when cheaper versions can enter depends on which patent or exclusivity blocks biosimilars or interchangeability in a given country.
What’s the typical timeline for biosimilar entry once patents end?
Even after key patents related to the originator are no longer enforceable, biosimilars may still face barriers tied to:
- remaining “late” patents (new formulations, uses, methods of treatment)
- regulatory exclusivity rules in the region
- patent litigation outcomes, which can delay launch even if some patents expire
Which patents matter most for adalimumab?
For adalimumab, the patents most relevant to biosimilar timing are usually those that protect:
- the drug substance (the antibody itself)
- manufacturing or formulation details
- specific medical uses or treatment regimens (depending on how those claims were written)
Why might the answer differ by country?
Patent terms, patent coverage, and any linkage between regulatory approval and patent status differ by jurisdiction. So the effective “expiry” date that affects biosimilar launch can vary between, for example, the U.S. and Europe.
Need the exact date for your country?
If you tell me which country (for example, United States vs. UK vs. EU), I can narrow down the relevant patent/exclusivity timeline for that jurisdiction and explain what it means for biosimilar entry there.